• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中药中难吸收的活性成分的 PK-PD 关系:肠道微生物代谢酶解释:以去氢紫堇碱为例。

PK-PD relationship of poorly absorbable active ingredients from traditional Chinese medicines explaining by metabolic enzyme of gut microbiota: A case study of Dehydrocorydaline.

机构信息

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China.

School of Pharmacy, Jilin Medical University, Jilin 132013, China.

出版信息

J Pharm Biomed Anal. 2025 Jan 1;252:116478. doi: 10.1016/j.jpba.2024.116478. Epub 2024 Sep 17.

DOI:10.1016/j.jpba.2024.116478
PMID:39306946
Abstract

Many active ingredients in traditional Chinese medicines generally have the characteristic of poor oral absorption but definite efficacy. It is necessary to establish a comprehensive technical system to explain the "PK-PD relationship" of them. Dehydrocorydaline (DHC), the quality control component in the Chinese patent drug "Kedaling Tablets", has poor oral absorption but clear efficacy for coronary heart disease. Using DHC as a model drug, the changes in absorption and pharmacological effects of DHC in rats before and after inhibiting nitroreductase (NR) from gut microbiota were studied. The results showed that after inhibiting of NR activity, the plasma concentration of DHC in rats was decreased, the serum level of total cholesterol, triglyceride and low-density lipoprotein cholesterol were significantly increased. The levels of tumor necrosis factor-α, interleukin-1β, hypersensitive C-reactive protein, intercellular cell adhesion molecule-1 and Monocyte chemoattractant protein-1 were significantly increased, and pathological sections also showed that the efficacy of DHC decreased after inhibiting the activity of NR. We further investigated the drug metabolism of DHC under NR and found that DHC was metabolized into a hydrogenated metabolite, which may have stronger membrane permeability. In summary, NR may mediate the absorption degree and efficacy of DHC in vivo by metabolizing DHC into absorbable metabolite.

摘要

许多中药的有效成分通常具有口服吸收差但疗效确切的特点。有必要建立一个综合技术体系来解释它们的“PK-PD 关系”。去氢紫堇碱(DHC)是中药专利药“克达令片”的质量控制成分,对冠心病具有良好的口服吸收和疗效。本研究以 DHC 为模型药物,研究了抑制肠道微生物群硝基还原酶(NR)前后 DHC 在大鼠体内的吸收和药效变化。结果表明,NR 活性被抑制后,大鼠血浆中 DHC 浓度降低,总胆固醇、甘油三酯和低密度脂蛋白胆固醇血清水平显著升高。肿瘤坏死因子-α、白细胞介素-1β、超敏 C 反应蛋白、细胞间黏附分子-1 和单核细胞趋化蛋白-1 水平也显著升高,病理切片也表明 NR 活性被抑制后 DHC 的疗效降低。我们进一步研究了 NR 下 DHC 的药物代谢情况,发现 DHC 被代谢成一种氢化代谢物,可能具有更强的膜通透性。综上所述,NR 可能通过将 DHC 代谢为可吸收的代谢物来调节 DHC 在体内的吸收程度和疗效。

相似文献

1
PK-PD relationship of poorly absorbable active ingredients from traditional Chinese medicines explaining by metabolic enzyme of gut microbiota: A case study of Dehydrocorydaline.中药中难吸收的活性成分的 PK-PD 关系:肠道微生物代谢酶解释:以去氢紫堇碱为例。
J Pharm Biomed Anal. 2025 Jan 1;252:116478. doi: 10.1016/j.jpba.2024.116478. Epub 2024 Sep 17.
2
Organic Cation Transporter 1 and 3 Contribute to the High Accumulation of Dehydrocorydaline in the Heart.有机阳离子转运体 1 和 3 有助于去氢紫堇碱在心脏中的高积累。
Drug Metab Dispos. 2020 Oct;48(10):1074-1083. doi: 10.1124/dmd.120.000025. Epub 2020 Jul 28.
3
The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: A review.肠道微生物群与中药生物活性成分的相互作用:综述。
Pharmacol Res. 2020 Jul;157:104824. doi: 10.1016/j.phrs.2020.104824. Epub 2020 Apr 25.
4
[Interaction of effective ingredients from traditional Chinese medicines with intestinal microbiota].[中药有效成分与肠道微生物群的相互作用]
Zhongguo Zhong Yao Za Zhi. 2016 May;41(10):1766-1772. doi: 10.4268/cjcmm20161002.
5
LC-MS/MS determination and pharmacokinetic study of dehydrocorydaline in rat plasma after oral administration of dehydrocorydaline and Corydalis yanhusuo extract.口服延胡索乙素和延胡索提取物后大鼠血浆中延胡索乙素的LC-MS/MS测定及药代动力学研究
Molecules. 2014 Oct 13;19(10):16312-26. doi: 10.3390/molecules191016312.
6
Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?肠道微生物群能否解决传统草药口服生物利用度的难题?
J Ethnopharmacol. 2016 Feb 17;179:253-64. doi: 10.1016/j.jep.2015.12.031. Epub 2015 Dec 23.
7
Kidney-tonifying blood-activating decoction delays ventricular remodeling in rats with chronic heart failure by regulating gut microbiota and metabolites and p38 mitogen-activated protein kinase/p65 nuclear factor kappa-B/aquaporin-4 signaling pathway.补肾活血汤通过调节肠道微生物群和代谢物以及 p38 丝裂原活化蛋白激酶/p65 核因子 κB/水通道蛋白 4 信号通路延缓慢性心力衰竭大鼠心室重构。
J Ethnopharmacol. 2024 Aug 10;330:118110. doi: 10.1016/j.jep.2024.118110. Epub 2024 Apr 3.
8
Gut microbiota affects the efficacy of Danggui Buxue Tang by affecting plasma concentration of active ingredients.肠道微生物群通过影响活性成分的血浆浓度来影响当归补血汤的疗效。
J Ethnopharmacol. 2021 Apr 24;270:113835. doi: 10.1016/j.jep.2021.113835. Epub 2021 Jan 16.
9
Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE mice.TSG 通过抑制炎症反应和调节肠道菌群来防治载脂蛋白 E 基因敲除小鼠的动脉粥样硬化。
J Ethnopharmacol. 2020 Jan 30;247:112232. doi: 10.1016/j.jep.2019.112232. Epub 2019 Oct 10.
10
Polysaccharides and glycosides from Aralia echinocaulis protect rats from arthritis by modulating the gut microbiota composition.刺五加中的多糖和糖苷通过调节肠道微生物群落组成来保护大鼠免受关节炎的侵害。
J Ethnopharmacol. 2021 Apr 6;269:113749. doi: 10.1016/j.jep.2020.113749. Epub 2020 Dec 25.